Bay City Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Damora TherapeuticsNASDAQ: DMRANov 2025SEC filingmedium confidence
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
Copenhagen, US
Board seatCarl Goldfischer· per SEC Form D · $285M raise · filed Nov 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.